Tag: PXS

Pharmaxis PXS ASX Bronchitol FDA myelofibrosis

Pharmaxis secures US FDA approval for Bronchitol, sales to bankroll development of myelofibrosis drug candidate

In what has been described as a “transformational step” Pharmaxis (ASX: PXS) has collared United States Food and Drug Administration approval for its Bronchitol drug (mannitol) to be used in the count...
Pharmaxis ASX PXS Phase 1 clinical trial NASH IPF fibrotic disease

Pharmaxis takes firm steps towards commercialising suite of fibrotic disease treatments

Pharmaceutical company Pharmaxis (ASX: PXS) has taken another step towards developing a useful treatment for debilitating fibrotic diseases such as Non‐Alcoholic Steatohepatitis (NASH) and Idiopathic ...
Pharmaxis ASX PXS Phase 1 clinical trial safety LOXL2 drug fibrotic disease treatment

Pharmaxis Phase 1 clinical trial proves safety of new LOXL2 drug in fibrotic disease treatment

Pharmaceutical company Pharmaxis (ASX: PXS) has returned positive results from a Phase 1 clinical trial for the first of its Lysyl Oxidase Like 2 (LOXL2) inhibitor compounds being developed to treat f...

RECENT POSTS

STOCK SUMMARY

FOLLOW US

HOT TOPICS

TRENDING POSTS